HER2-negative Breast Cancer – A Pathologist’s Perspective
As the treatment landscape for breast cancer evolves, so too must the interpretation of pathology results. For HER2-negative breast cancer (IHC 0, 1+, and 2+ [ISH-negative]), interpretation can have a significant impact on treatment decisions and patient prognosis. Professor Johan Hartman shares his experience and insights.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen